granzyme K CRISPR/Cas9 KO Plasmid (h): sc-407038
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- granzyme K CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the granzyme K genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: granzyme K Antibody (GM6C3): sc-56125
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
granzyme K CRISPR/Cas9 KO Plasmid (h) | sc-407038 | 20 µg | $397.00 |
Overview
GZMK encodes granzyme K, a trypsin-like serine protease stored in cytotoxic lymphocyte granules and released at immune synapses to shape target-cell responses and inflammatory signaling. Granzyme K activity is linked to cytotoxic effector programs, proteolytic remodeling of intracellular substrates, and crosstalk with apoptotic and stress-response pathways that influence tissue damage and immune regulation. In human immunity, GZMK expression is characteristic of activated CD8+ T cells and NK cell subsets and is frequently used as a marker of immune activation and cytotoxic differentiation. Dysregulated GZMK expression has been associated with inflammatory microenvironments and immune-mediated pathology, supporting its study in infection, autoimmunity, and tumor immunology contexts.
granzyme K CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GZMK gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GZMK together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GZMK open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish granzyme K protein expression.
This CRISPR knockout system enables efficient generation of GZMK-deficient cell models for investigation of granzyme K signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GZMK exon(s) critical for granzyme K function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GZMK genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by granzyme K CRISPR/Cas9 KO Plasmid (h) and granzyme K CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GZMK locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by granzyme K HDR Plasmid (h) and granzyme K HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GZMK homology arms to support homology-directed repair at defined GZMK target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.